Weight Loss Injections and 'Ompezic': Sorting the Facts from the Search Terms

Why 'ompezic' almost certainly means semaglutide, and why the licence distinction matters

Misspellings cluster around brands people have heard discussed: a celebrity interview, a friend's prescription, a headline. 'Ompezic' is one of those routes to Ozempic, and Ozempic is semaglutide at doses designed for blood-sugar management in type 2 diabetes. The NHS guidance on semaglutide is clear that Wegovy (a separately approved formulation at a higher weekly dose) is the version licensed for weight management in adults without diabetes.

This matters for two reasons. First, a prescriber writing Ozempic for weight loss would be doing so outside its UK licence, which carries real clinical and legal implications. Second, the dosing schedules differ: Wegovy's maintenance dose reaches 2.4mg weekly, while the diabetes licence uses different strengths. Mixing them up is not a technicality, it affects what you receive, how it's monitored, and who is responsible for that oversight. If you've seen Ozempic discussed in the context of weight loss, the medicine people are usually describing (or hoping to access) is Wegovy, or more recently Mounjaro, and our weight loss injection page explains how each option works and what separates them.

One misconception worth letting go quietly: the idea that Ozempic is simply a cheaper or more available route to the same outcome. It isn't a substitute, and a legitimate prescriber won't frame it that way.

What the two licensed injections actually do differently

Wegovy (semaglutide) works by mimicking a gut hormone called GLP-1, which signals fullness to the brain, slows how quickly the stomach empties, and reduces appetite. It's injected once a week, starting at 0.25mg and titrated over roughly five months to 2.4mg. In the STEP 1 trial (68 weeks, adults with obesity, published in the New England Journal of Medicine) participants lost an average of around 15% of body weight alongside lifestyle changes.

Mounjaro (tirzepatide) takes a different approach: it activates both the GLP-1 receptor and a second one called GIP, making it the only dual-agonist in this class available in the UK. Trial data from the SURMOUNT programme, involving thousands of adults with obesity, showed average weight reductions of around 20–21% at the highest dose over 72 weeks. Whether that additional mechanism translates into a meaningful advantage for a specific patient is something only a prescriber can assess, there are contraindications, tolerability differences, and individual health histories to weigh up, and if you want to see how the options stack up side by side, our guide to the 3 weight loss injections currently available in the UK walks through each one in detail. You can read a fuller comparison on the weight loss overview page.

Both injections are subcutaneous (injected just under the skin at the abdomen, thigh, or upper arm) and both are supplied as pre-filled pens. Rotating injection sites is standard practice to avoid localised reactions.

Who these injections are licensed for, and what clinical assessment covers

Under their UK licences, both Wegovy and Mounjaro are for adults with a BMI of 30 or above, or 27 and above if at least one weight-related condition is present, things like high blood pressure, raised cholesterol, prediabetes, or obstructive sleep apnoea. Lower BMI thresholds can apply for certain ethnic backgrounds under UK guidance. BMI alone doesn't determine suitability; a prescriber also looks at your medical history, current medicines, and whether there are any conditions that would make either injection unsuitable.

A prescriber cannot issue a prescription without that assessment, and that assessment cannot be replaced by a questionnaire alone. At nume, a GPhC-registered Independent Prescriber personally reviews every consultation the same day, not software, not an automated pathway. If you're curious about what a GP-led route looks like, the GP weight loss injections page covers how NHS prescribing works in practice, including current phased eligibility criteria.

There are also clear exclusions. These injections are not licensed for use during pregnancy, breastfeeding, or when trying to conceive, and they are not licensed for anyone under 18. A history of medullary thyroid carcinoma, certain pancreatic conditions, or specific gut disorders requires careful prescriber discussion before any treatment begins.

Side effects, safety signals, and what to watch for

The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping. These tend to peak when starting or after a dose increase, then settle for most people within the first couple of weeks. Fatigue, headache, and mild dizziness are also reported. Injection-site redness or itching is possible; rotating sites helps.

A more serious but infrequent risk is acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update drawing attention to this, advising patients to seek urgent medical help for severe stomach pain that spreads to the back, with or without vomiting. That update applies to the whole GLP-1 class. If you want to understand the full side-effect picture before deciding, the FAQs section addresses the questions our prescribers hear most often. Side effects or concerns during treatment can also be raised through our aftercare team, available seven days a week.

For completeness: patients can report any suspected side effect to the MHRA directly at Yellow Card, and this includes adverse reactions from medicines sourced anywhere, legitimate or otherwise.

If you're weighing up the practicalities of cost alongside everything else, the guide to buying weight loss injections safely in the UK explains what a transparent private prescription actually includes and why headline prices often leave out key parts of that picture. For a closer look at how reviews and real-world experience shape what patients choose, the weight loss injection reviews page brings together patient feedback across the available treatments. When you're ready to take the next step, start your free consultation and a prescriber will review your details the same day.